{
    "clinical_study": {
        "@rank": "58955", 
        "arm_group": [
            {
                "arm_group_label": "Herceptin\u2122 (Her)", 
                "arm_group_type": "Active Comparator", 
                "description": "Herceptin\u2122 (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy"
            }, 
            {
                "arm_group_label": "Herceptin\u2122+Chemo", 
                "arm_group_type": "Active Comparator", 
                "description": "Herceptin\u2122 (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: To compare efficacy, toxicity and quality of life of the sequential\n      administration of Her alone followed, at PD, by the combination with Chemotherapy (Arm A)\n      vs. the upfront combination of Her and Chemotherapy (Arm B) in patients with\n      advanced/metastatic breast cancer.\n\n      PURPOSE: Trial SAKK 22/99 addresses clinically relevant and currently unresolved questions\n      regarding the optimal use of Herceptin in the treatment of patients with advanced/metastatic\n      breast cancer."
        }, 
        "brief_title": "Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed HER2-overexpressing metastatic breast carcinoma\n\n          -  Clinically or radiologically measurable or evaluable disease\n\n               -  Bidimensionally or unidimensionally measurable lesions\n\n          -  No ascitic, pleural, or pericardial effusions, osteoblastic bone metastases, or\n             carcinomatous lymphangitis of the lung as only indicator lesion\n\n          -  No known clinical brain or meningeal involvement\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 to 70\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  ECOG 0-1 OR\n\n          -  SAKK 0-1\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  Hemoglobin at least 10 g/dL\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Absolute neutrophil count at least 2,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  SGOT and/or SGPT no greater than 2 times upper limit of normal (ULN) (3 times ULN if\n             proven liver metastases) OR\n\n          -  No SGOT and/or SGPT greater than 1.5 times ULN if alkaline phosphatase greater than\n             2.5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 1.25 times ULN\n\n        Cardiovascular:\n\n          -  LVEF normal\n\n          -  No history of atrial ventricular arrhythmia, congestive heart failure, or angina\n             pectoris, even if medically controlled\n\n          -  No history of second or third-degree heart blocks\n\n          -  No uncontrolled hypertension\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No pre-existing motor or sensory neuropathy grade 2 or greater\n\n          -  No psychiatric disorder that would preclude informed consent\n\n          -  No other prior malignancy except curatively treated nonmelanoma skin cancer or\n             carcinoma in situ of the cervix\n\n          -  No definite contraindications for use of corticosteroids\n\n          -  No other concurrent serious illness or medical condition\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Prior adjuvant or neoadjuvant chemotherapy allowed\n\n          -  No more than 2 prior chemotherapy regimens for metastatic disease\n\n          -  No prior cumulative dose of doxorubicin greater than 240 mg/m^2\n\n          -  No prior cumulative dose of epirubicin greater than 360 mg/m^2\n\n          -  No prior taxanes\n\n        Endocrine therapy:\n\n          -  Prior hormonal therapy as adjuvant treatment or for metastatic disease allowed\n\n          -  No concurrent corticosteroids unless started more than 6 months prior to study and at\n             low doses (i.e., no greater than 20 mg methylprednisolone or equivalent)\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No other concurrent anticancer drugs\n\n          -  No other concurrent experimental drugs\n\n          -  No concurrent bisphosphonates unless initiated more than 3 months prior to study\n\n               -  Chronic use allowed provided bone metastases are not sole indicator lesions"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004935", 
            "org_study_id": "SAKK 22/99", 
            "secondary_id": [
                "SWS-SAKK-22/99", 
                "EU-99028"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Herceptin\u2122 (Her)", 
                "description": "Herceptin\u2122 (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy", 
                "intervention_name": "Herceptin\u2122 (Her)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin\u2122+Chemo", 
                "description": "Herceptin\u2122 (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy", 
                "intervention_name": "Herceptin\u2122 (Her) + chemo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "May 7, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "Institut Bergonie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20141"
                    }, 
                    "name": "European Institute of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varese", 
                        "country": "Italy", 
                        "zip": "21100"
                    }, 
                    "name": "Ospedale di Circolo e Fondazione Macchi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarau", 
                        "country": "Switzerland", 
                        "zip": "CH-5001"
                    }, 
                    "name": "Kantonsspital Aarau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baden", 
                        "country": "Switzerland", 
                        "zip": "CH-5404"
                    }, 
                    "name": "Kantonsspital Baden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4031"
                    }, 
                    "name": "Universitaetsspital-Basel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "Inselspital Bern"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mendrisio", 
                        "country": "Switzerland", 
                        "zip": "CH-6850"
                    }, 
                    "name": "Ospedale Beata Vergine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rheinfelden", 
                        "country": "Switzerland", 
                        "zip": "CH-4310"
                    }, 
                    "name": "Praxis Dr. Beretta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital - St. Gallen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thun", 
                        "country": "Switzerland", 
                        "zip": "3600"
                    }, 
                    "name": "Regionalspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "UniversitaetsSpital Zuerich"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "8038"
                    }, 
                    "name": "Onkozentrum"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Italy", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase III Trial of Herceptin\u00ae Followed by Chemotherapy Plus Herceptin\u00ae Versus the Combination of Herceptin\u00ae and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.", 
        "overall_official": {
            "affiliation": "Istituto Oncologico della Svizzera Italiana IOSI", 
            "last_name": "Pagani Olivia, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to progression on combined HerChemo (TTPHerChemo)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004935"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Time to first progression", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Toxicity", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Predictive value of serum HER2/neu ECD levels on clinical outcome", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Conversion rate of estrogen receptor status", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Association of immunoprofiles of erbB-1, erbB-2, erbB-3 and erbB-4 with clinical outcome", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Swiss Group for Clinical Cancer Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Swiss Group for Clinical Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1999", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {
        "Centre Hospitalier Universitaire Vaudois": "46.52 6.634", 
        "European Institute of Oncology": "45.464 9.188", 
        "Inselspital Bern": "46.948 7.445", 
        "Institut Bergonie": "44.838 -0.579", 
        "Kantonsspital - St. Gallen": "47.424 9.371", 
        "Kantonsspital Aarau": "47.391 8.046", 
        "Kantonsspital Baden": "47.474 8.306", 
        "Onkozentrum": "47.369 8.539", 
        "Ospedale Beata Vergine": "45.87 8.982", 
        "Ospedale di Circolo e Fondazione Macchi": "45.818 8.826", 
        "Praxis Dr. Beretta": "47.552 7.793", 
        "Regionalspital": "46.748 7.626", 
        "UniversitaetsSpital Zuerich": "47.369 8.539", 
        "Universitaetsspital-Basel": "47.557 7.593"
    }
}